Det her kan blive meget vigtigt for Epicept. Jeg har ikek megen fidus til ledelsen i Epicpet, men aktien er relativt billig. Jeg mener at kunne huske fra en præsentation,atdet har kunen blvie en block-buster.
Press Release Source: EpiCept Corporation On Monday February 7, 2011, 12:01 am EST
TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept™ NP-1 (NP-1) in chemotherapy-induced peripheral neuropathy (CPN). EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.
The multi-center, double-blind, randomized, placebo-controlled study was conducted by the National Cancer Institute (NCI)-funded Community Clinical Oncology Program. More than 460 cancer survivors suffering from painful CPN were enrolled in the six-week study. The results of the trial in the intent to treat (ITT) population demonstrated that the change in average daily neuropathy intensity scores in the NP-1 group achieved a statistically significant reduction in CPN intensity versus placebo (p
Press Release Source: EpiCept Corporation On Monday February 7, 2011, 12:01 am EST
TARRYTOWN, N.Y.--(BUSINESS WIRE)-- Regulatory News:
EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT) today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept™ NP-1 (NP-1) in chemotherapy-induced peripheral neuropathy (CPN). EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.
The multi-center, double-blind, randomized, placebo-controlled study was conducted by the National Cancer Institute (NCI)-funded Community Clinical Oncology Program. More than 460 cancer survivors suffering from painful CPN were enrolled in the six-week study. The results of the trial in the intent to treat (ITT) population demonstrated that the change in average daily neuropathy intensity scores in the NP-1 group achieved a statistically significant reduction in CPN intensity versus placebo (p
7/2 2011 20:05 faurschou 0
38693 Ledelsen har ikke på noget tidspunkt været i nærheden af rettidig omhu, og kassen er næsten tom. Hvis de gør som de plejer, så er det ikke til fordel for aktionærerne.
Men NP-1 kan gå hen og blive en rigtig god smertebehandling. Jeg kunne dog godt tænke mig lidt nærmere information om effekten af NP-1 i studiet.
Men NP-1 kan gå hen og blive en rigtig god smertebehandling. Jeg kunne dog godt tænke mig lidt nærmere information om effekten af NP-1 i studiet.
9/2 2011 20:29 faurschou 038765 Og så kom der igen en rettet emission fra Epicept
EpiCept to Raise $7.1 Million in Registered Direct Offering
TARRYTOWN, N.Y.--(BUSINESS WIRE)-- EpiCept Corporation (Nasdaq and OMX Stockholm Exchange: EPCT) announced today that it has entered into definitive agreements for the purchase of approximately 8.9 million shares of its common stock at $0.80 per share, and five-year warrants to purchase up to approximately 3.6 million shares of common stock at an exercise price of $0.75 per share. EpiCept will receive approximately $6.6 million in net proceeds from the offering. The offering is expected to close on or about February 10, 2011, subject to customary closing conditions.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM) acted as the exclusive placement agent for the offering.
Net proceeds from the offering will be used to meet working capital needs while the Company seeks to close the key element of its previously-announced financing plan, and for general corporate purposes.
EpiCept to Raise $7.1 Million in Registered Direct Offering
TARRYTOWN, N.Y.--(BUSINESS WIRE)-- EpiCept Corporation (Nasdaq and OMX Stockholm Exchange: EPCT) announced today that it has entered into definitive agreements for the purchase of approximately 8.9 million shares of its common stock at $0.80 per share, and five-year warrants to purchase up to approximately 3.6 million shares of common stock at an exercise price of $0.75 per share. EpiCept will receive approximately $6.6 million in net proceeds from the offering. The offering is expected to close on or about February 10, 2011, subject to customary closing conditions.
Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM) acted as the exclusive placement agent for the offering.
Net proceeds from the offering will be used to meet working capital needs while the Company seeks to close the key element of its previously-announced financing plan, and for general corporate purposes.
13/2 2011 14:24 digafarm 038886 Metoden virker bekendt; god nyhed efterfulgt af en emission. Jeg solgte selv fra da den ventede nyhed om NP-1 studierne kom og ganske rigtig kom emissionen dagen efter. Jeg afventer nu min entré i aktien igen. I en mail til en svensk investor har Bob Cook skrevet at arbejdet med at få en aftale på plads samt at sikre virksomheden kapital til den lange bane trækker ud. Dermed ser jeg ingen umiddelbare triggers i den korte bane hvorfor jeg tror vi skal ned under 4 kroner. (På trods af at virksomheden er sikret kapital til Q4 2011 med denne emission).
Jack Talley fortæller om EPCT's nuværende situation og fremadrettede handlinger på en konference imorgen 11:30 Eastern time.
Jack Talley fortæller om EPCT's nuværende situation og fremadrettede handlinger på en konference imorgen 11:30 Eastern time.
21/2 2011 22:28 digafarm 039275 Årsregnskab for 2010 samt Q4 fremlægges på torsdag. Vi vil højst sandsynligt se en lille stigning frem til denne dag, drevet af Avanza, herefter vil kursen forsætte sin nedadgående trend indtil den finder et nedre støttepunkt (Fastholder min tidligere påstand om at denne findes under 4 kroner). Dette skyldes at Jack Talley ikke vil komme med nogle nye informationer samt forevise forsvindende små indtægter fra salg af Ceplene gennem IDIS samt Meda.
23/2 2011 00:10 digafarm 039323 Tog idag et dyk på 9 pct. på NASDAQ efter en stille dag i Sverige, under forholdvis høj omsætning. Lukkede i $0,60 modsvarende en kurs i 3,9 SEK.
